Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries – Johnson & Johnson

by

  1. Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries Johnson & Johnson
  2. J&J will not enforce TB drug bedaquiline patent in many countries STAT
  3. MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries MSF Access Campaign
  4. MSF welcomes J&J’s decision to not enforce unnecessary patents on key TB drug Doctors Without Borders (MSF-USA)
  5. Unitaid slams J&J over pricing and patents for a tuberculosis drug STAT
  6. View Full Coverage on Google News

Read original article here

Leave a Comment